We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hologic Leads Campaign to Emphasize Routine Cervical Cancer Screening
Read MoreHide Full Article
Key Takeaways
HOLX launched the Ultimate Defense campaign in January to promote routine Pap HPV screening.
Hologic highlights Pap HPV co-testing, which offers greater sensitivity than either test alone.
HOLX is expanding Genius Digital Diagnostics, using FDA-cleared AI to ease lab shortages and screening.
January is observed as Cervical Cancer Awareness Month, and Hologic (HOLX - Free Report) has long been a leader in cervical cancer screening. The company developed the first FDA-approved liquid-based cytology test, the ThinPrep Pap test, as well as the first FDA-approved mRNA-based HPV test, the Aptima HPV Assay. However, research shows that Co-testing — combining a Pap test with an HPV test — offers greater sensitivity for cervical cancer screening than either test used on its own.
Per a Grand View Research report, the global HPV testing and Pap test market was valued at $6.18 billion in 2024 and is projected to witness a CAGR of 7.2% through 2033. Cervical cancer is largely preventable and treatable, yet incidence rates are rising, partly due to many women missing the recommended screenings. Closing these gaps requires a multi-pronged approach, starting with awareness and patient education, and follow-up on any abnormal results.
Each January, the company emphasizes the importance of Pap + HPV screening in preventing cervical cancer by teaming up with healthcare professionals, women’s health advocates and cervical cancer survivors. Hologic recently announced the launch of Ultimate Defense, featuring women’s professional basketball player Erica Wheeler. The new U.S.-based educational campaign is designed to increase awareness about the importance of routine cervical cancer screening and encourage women to discuss recommended care with their healthcare providers.
In 2024, Hologic introduced Genius Digital Diagnostics, powered by the Genius Cervical AI algorithm. The System is the first and only FDA-cleared digital cytology system that combines deep-learning-based AI with advanced volumetric imaging technology to help identify pre-cancerous lesions and cervical cancer cells.
With implementation expanding to more labs worldwide, the platform’s workflow advantages are helping address the growing labor shortages and enable screening in regions with limited infrastructure. The full rollout is expected to be a multiyear process, contributing to the company’s growth for the next several quarters.
What Are Hologic’s Peers Up to?
Boston Scientific (BSX - Free Report) has entered into a definitive agreement to acquire Penumbra in a cash and stock transaction valued at roughly $14.5 billion. The acquisition is expected to expand Boston Scientific's cardiovascular portfolio and address the increasing prevalence of vascular diseases. With completion planned in 2026, the deal would provide BSX with a scaled entry into mechanical thrombectomy and neurovascular, both viewed as key strategic adjacencies.
Medtronic (MDT - Free Report) secured the FDA’s 510(k) clearance of its MiniMed Go app. The MiniMed Go system is a smart diabetes management solution that connects the InPen smart insulin pen and Abbott’s Instinct sensor through the MiniMed Go app. Compatibility of the Simplera sensor with MiniMed Go is currently under FDA review. Medtronic expects the U.S. commercial launch of the MiniMed Go system to begin this spring.
HOLX Stock Price Performance, Valuation and Estimates
In the past six months, Hologic shares have risen 17.2% compared with the industry’s 10.6% growth.
Image Source: Zacks Investment Research
Hologic is trading at a forward five-year price-to-sales (P/S) of 3.85X, lower than its median and 4.18X industry average.
Image Source: Zacks Investment Research
Take a look at how Hologic’s fiscal 2026 and 2027 earnings are shaping up.
Image: Bigstock
Hologic Leads Campaign to Emphasize Routine Cervical Cancer Screening
Key Takeaways
January is observed as Cervical Cancer Awareness Month, and Hologic (HOLX - Free Report) has long been a leader in cervical cancer screening. The company developed the first FDA-approved liquid-based cytology test, the ThinPrep Pap test, as well as the first FDA-approved mRNA-based HPV test, the Aptima HPV Assay. However, research shows that Co-testing — combining a Pap test with an HPV test — offers greater sensitivity for cervical cancer screening than either test used on its own.
Per a Grand View Research report, the global HPV testing and Pap test market was valued at $6.18 billion in 2024 and is projected to witness a CAGR of 7.2% through 2033. Cervical cancer is largely preventable and treatable, yet incidence rates are rising, partly due to many women missing the recommended screenings. Closing these gaps requires a multi-pronged approach, starting with awareness and patient education, and follow-up on any abnormal results.
Each January, the company emphasizes the importance of Pap + HPV screening in preventing cervical cancer by teaming up with healthcare professionals, women’s health advocates and cervical cancer survivors. Hologic recently announced the launch of Ultimate Defense, featuring women’s professional basketball player Erica Wheeler. The new U.S.-based educational campaign is designed to increase awareness about the importance of routine cervical cancer screening and encourage women to discuss recommended care with their healthcare providers.
In 2024, Hologic introduced Genius Digital Diagnostics, powered by the Genius Cervical AI algorithm. The System is the first and only FDA-cleared digital cytology system that combines deep-learning-based AI with advanced volumetric imaging technology to help identify pre-cancerous lesions and cervical cancer cells.
With implementation expanding to more labs worldwide, the platform’s workflow advantages are helping address the growing labor shortages and enable screening in regions with limited infrastructure. The full rollout is expected to be a multiyear process, contributing to the company’s growth for the next several quarters.
What Are Hologic’s Peers Up to?
Boston Scientific (BSX - Free Report) has entered into a definitive agreement to acquire Penumbra in a cash and stock transaction valued at roughly $14.5 billion. The acquisition is expected to expand Boston Scientific's cardiovascular portfolio and address the increasing prevalence of vascular diseases. With completion planned in 2026, the deal would provide BSX with a scaled entry into mechanical thrombectomy and neurovascular, both viewed as key strategic adjacencies.
Medtronic (MDT - Free Report) secured the FDA’s 510(k) clearance of its MiniMed Go app. The MiniMed Go system is a smart diabetes management solution that connects the InPen smart insulin pen and Abbott’s Instinct sensor through the MiniMed Go app. Compatibility of the Simplera sensor with MiniMed Go is currently under FDA review. Medtronic expects the U.S. commercial launch of the MiniMed Go system to begin this spring.
HOLX Stock Price Performance, Valuation and Estimates
In the past six months, Hologic shares have risen 17.2% compared with the industry’s 10.6% growth.
Image Source: Zacks Investment Research
Hologic is trading at a forward five-year price-to-sales (P/S) of 3.85X, lower than its median and 4.18X industry average.
Image Source: Zacks Investment Research
Take a look at how Hologic’s fiscal 2026 and 2027 earnings are shaping up.
Image Source: Zacks Investment Research
HOLX stock currently carries a Zacks Rank #2 (Buy).You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.